Evaluation of Felodipine As a Potential Perpetrator of Pharmacokinetic Drug-drug Interactions

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2014 Jul 17

PMID 25028073

Citations 8

Authors

Ben D Snyder

Andrew Rowland

Thomas M Polasek

John O Miners

Matthew P Doogue

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp).

Methods: Felodipine extended-release 10 mg was administered daily to six healthy subjects for 7 days (days 1-7). Subjects were administered a modified Inje cocktail comprising the selective probe substrates caffeine 100 mg (CYP1A2), losartan 25 mg (CYP2C9), omeprazole 20 mg (CYP2C19), dextromethorphan 30 mg (CYP2D6), midazolam 2 mg (CYP3A) and digoxin 250 μg (P-gp) on day 0 (prior to felodipine exposure) and day 7 (after felodipine exposure). Plasma samples were collected over 24 h and drug concentrations measured by UPLC-MS/MS.

Results: The geometric means of the area under the plasma concentration-time curve ratios (probe AUC after felodipine exposure/probe AUC prior to felodipine exposure) and 95% confidence intervals for each probe were: caffeine 0.91 (0.64-1.30), losartan 1.05 (0.95-1.15), omeprazole 1.17 (0.78-1.76), dextromethorphan 1.46 (1.00-2.12), midazolam 1.23 (0.99-1.52) and digoxin 1.01 (0.89-1.15).

Conclusion: Felodipine may be a weak in vivo inhibitor of CYP3A and CYP2D6 but is unlikely to act as a significant perpetrator of PK-DDIs.

Citing Articles

Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.

Barth A, Perry C, Shabbir S, Zamek-Gliszczynski M, Thomas S, Dumont E Clin Transl Sci. 2023; 16(4):647-661.

PMID: 36642822 PMC: 10087077. DOI: 10.1111/cts.13477.

Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.

Dai X, Karol M, Hitron M, Hard M, Goulet M, McLaughlin C Clin Pharmacol Drug Dev. 2021; 10(8):824-839.

PMID: 34107166 PMC: 8453567. DOI: 10.1002/cpdd.961.

Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry.

Heo J, Kim H, Lee G, Ohk B, Lee S, Song K Pharmaceutics. 2018; 10(3).

PMID: 30004443 PMC: 6160928. DOI: 10.3390/pharmaceutics10030079.

Combined Antihypertensive Effect of Paeoniflorin Enriched Extract and Metoprolol in Spontaneously Hypertensive Rats.

Li B, Yang Z, Lei S, Su J, Jin Z, Chen S Pharmacogn Mag. 2018; 14(53):44-52.

PMID: 29576700 PMC: 5858241. DOI: 10.4103/pm.pm_483_16.

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.

van Dyk M, Marshall J, Sorich M, Wood L, Rowland A Eur J Clin Pharmacol. 2018; 74(7):913-920.

PMID: 29572563 DOI: 10.1007/s00228-018-2450-4.

References

Kirby B, Kharasch E, Thummel K, Narang V, Hoffer C, Unadkat J . Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J Clin Pharmacol. 2006; 46(11):1313-9. DOI: 10.1177/0091270006292625. View

Greiner B, Eichelbaum M, Fritz P, Kreichgauer H, von Richter O, Zundler J . The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999; 104(2):147-53. PMC: 408477. DOI: 10.1172/JCI6663. View

Williamson K, Patterson J, McQueen R, Adams Jr K, Pieper J . Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998; 63(3):316-23. DOI: 10.1016/S0009-9236(98)90163-1. View

De Smet M, Schoors D, De Meyer G, Verbesselt R, Goldberg M, Fitzpatrick V . Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol. 1995; 40(6):571-5. PMC: 1365213. DOI: 10.1111/j.1365-2125.1995.tb05802.x. View

Lahiri D, Bye S, Nurnberger Jr J, Hodes M, Crisp M . A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested. J Biochem Biophys Methods. 1992; 25(4):193-205. DOI: 10.1016/0165-022x(92)90014-2. View

Ronn O, Blychert L, Edgar B, Raner S . Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men. Eur J Clin Pharmacol. 1990; 38(6):529-33. DOI: 10.1007/BF00278576. View

Harder S, STAIB A, Beer C, Papenburg A, Stille W, Shah P . 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988; 35(6):651-6. DOI: 10.1007/BF00637602. View

Kang B, Yang C, Cho H, Suh O, Shin W . Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002; 23(2):77-81. DOI: 10.1002/bdd.291. View

Smith S, Wilkins M, JACK D, Kendall M, Laugher S . Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol. 1987; 31(5):575-8. DOI: 10.1007/BF00606633. View

10.

Fuhr U, Jetter A, Kirchheiner J . Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007; 81(2):270-83. DOI: 10.1038/sj.clpt.6100050. View

11.

MEYER B, Muller F, Hundt H, Luus H, de la Rey N, Rothig H . The effects of felodipine on the pharmacokinetics of diazepam. Int J Clin Pharmacol Ther Toxicol. 1992; 30(4):117-21. View

12.

Ryu J, Song I, Sunwoo Y, Shon J, Liu K, Cha I . Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 2007; 82(5):531-40. DOI: 10.1038/sj.clpt.6100187. View

13.

Ma B, Prueksaritanont T, Lin J . Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000; 28(2):125-30. View

14.

Jalava K, Olkkola K, Neuvonen P . Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther. 1997; 61(4):410-5. DOI: 10.1016/S0009-9236(97)90191-0. View

15.

Oosterhuis B, Jonkman J, Andersson T, Zuiderwijk P, Jedema J . Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991; 32(5):569-72. PMC: 1368632. DOI: 10.1111/j.1365-2125.1991.tb03953.x. View

16.

Hsiao C, Wu Y, Hsu K . Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. Arzneimittelforschung. 2011; 61(8):444-51. DOI: 10.1055/s-0031-1296226. View

17.

Andersson T . Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996; 31(1):9-28. DOI: 10.2165/00003088-199631010-00002. View

18.

Olkkola K, Backman J, Neuvonen P . Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 55(5):481-5. DOI: 10.1038/clpt.1994.60. View

19.

Polasek T, Miners J . In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol. 2007; 3(3):321-9. DOI: 10.1517/17425255.3.3.321. View

20.

Polasek T, Elliot D, Lewis B, Miners J . Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004; 311(3):996-1007. DOI: 10.1124/jpet.104.071803. View